Results 1 to 10 of about 55,987 (284)

Seizures Associated With Bone Density Conservation Agents [PDF]

open access: greenJournal of Pharmacy Technology, 2022
Objective The purpose of this review is to discuss the existing literature regarding patients who have experienced seizures after administration of a bone density conservation agent (BDCA). Data Sources A comprehensive literature review was performed between September and October 2021 using the following keywords: osteoporosis/drug therapy, seizures ...
Kuan Sturgill, Justin P. Reinert
europepmc   +6 more sources

Therapeutic Drug Review on Romosozumab: The First Sclerostin Inhibitor [PDF]

open access: yesJournal of Clinical and Diagnostic Research, 2022
Osteoporosis is a progressive skeletal disorder which is characterised by low bone mass, normal mineralisation and abnormal bone microarchitecture. This disruption of bone microarchitecture causes subsequent increase in bone fragility and raises risk of ...
Vijay Kumar Jain   +3 more
doaj   +1 more source

When to Start and Stop Bone-Protecting Medication for Preventing Glucocorticoid-Induced Osteoporosis

open access: yesFrontiers in Endocrinology, 2021
Glucocorticoid-induced osteoporosis (GIOP) leads to fractures in up to 40% of patients with chronic glucocorticoid (GC) therapy when left untreated. GCs rapidly increase fracture risk, and thus many patients with anticipated chronic GC exposures should ...
Kaleen N. Hayes   +5 more
doaj   +1 more source

Denosumab treatment for osteopenia or osteoporosis in heart transplant recipients: Effects and safety

open access: yesTransplantation Reports, 2022
Background: Osteoporosis is a prevalent complication in heart transplant population. Denosumab is a monoclonal antibody that inhibits bone resorption approved for the treatment of corticosteroid-induced osteoporosis and potentially useful in heart ...
Juan C. Uzquiano   +5 more
doaj   +1 more source

Denosumab versus zoledronic acid in cases of surgically unsalvageable giant cell tumor of bone: A randomized clinical trial

open access: yesJournal of Bone Oncology, 2022
Background: Giant-cell tumor of bone (GCTB) is a relatively benign, but locally aggressive osteoclastogenic stromal tumour of the bone. Although denosumab has been approved as an monoclonal antibody against RANK ligand for the treatment of GCTB, few ...
Jiaji Yue, Wei Sun, Shenglong Li
doaj   +1 more source

Dental Evaluation Prior to Cancer Therapy

open access: yesFrontiers in Oral Health, 2022
A comprehensive oral examination and dental care prior to the start of cancer therapy is the standard of care in many cancer centers. This is because good oral health will likely minimize the undesirable complications such as opportunistic infections ...
Chee Weng Yong   +2 more
doaj   +1 more source

Contributions of Clinical and Technical Factors to Longitudinal Change in Trabecular Bone Score and Bone Density: A Registry‐Based Individual‐Level Analysis

open access: yesJournal of Bone and Mineral Research, 2023
Lumbar spine trabecular bone score (TBS), a gray‐level texture measure derived from spine dual‐energy X‐ray absorptiometry (DXA) images, is a bone mineral density (BMD)‐independent risk factor for fracture.
W. Leslie   +4 more
semanticscholar   +1 more source

Dentists’ Awareness of Medication-Related Osteonecrosis of the Jaw (Risk Factors, Drugs, and Prevention) in the Republic of Croatia

open access: yesActa Stomatologica Croatica, 2023
Antiresorptive drugs (AR) have been used for many years in the treatment of various bone conditions such as osteoporosis, osteopenia, Paget’s disease, bone metastases, multiple myeloma and the associated malignant hypercalcemia.
Sven Bival   +5 more
doaj   +1 more source

Association between triglyceride-glucose index and bone mineral density in US adults: a cross sectional study

open access: yesJournal of Orthopaedic Surgery and Research, 2023
Objective Disorders in glucose and lipid metabolism have been shown to exert an influence on bone metabolism. The TyG index, which combines measures of glucose and triglycerides, provides insights into the overall metabolic status.
Huixia Zhan   +4 more
semanticscholar   +1 more source

Effect of Romosozumab on Trabecular Bone Score Compared to Anti-Resorptive Agents in Postmenopausal Women with Osteoporosis

open access: yesJournal of Bone Metabolism, 2021
Background Romosozumab has shown significant improvement in bone mineral density (BMD) in previously reported trials. However, BMD reflects only bone strength and does not offer insight into the bone microarchitecture.
C. Jeong   +5 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy